Their study showed that DCIS patients with pathogenic variants in BRCA1/2 and PALB2 had a higher risk of developing invasive breast cancer than those without.
In addition to this, we also assessed the prognostic values of these alterations, and specifically in the HER2-positive breast cancer brain metastasis, we observed that the presence of PIK3CA ...
AstraZeneca (AZ) has received two separate recommendations from the National Institute for Health and Care Excellence (NICE) for use of its lung cancer drugs Tagrisso (osimertinib) and Imfinzi ...